Andes Biotechnologies


Andes Biotechnologies is developing a novel anticancer therapy based on the inactivation of a non-coding RNA target, that selectively eliminates tumor cells of many cancers without harming normal cells. The company is an interesting target for a licensing/trade-sale deal with a larger pharma or biotech player.


CEO: Cristian Hernandez

Board Members

  • Arturo Yudelevich
  • Pablo Valenzuela
  • Luis Burzio
  • Alexander Seelenberger
  • Felipe Camposano